Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Short-term Investments (2019 - 2025)

Historic Short-term Investments for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $814.1 million.

  • Madrigal Pharmaceuticals' Short-term Investments rose 628.14% to $814.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $814.1 million, marking a year-over-year increase of 628.14%. This contributed to the annual value of $826.2 million for FY2024, which is 5466.25% up from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Short-term Investments stood at $814.1 million, which was up 628.14% from $610.8 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Short-term Investments' 5-year high stood at $826.2 million during Q4 2024, with a 5-year trough of $27.2 million in Q4 2022.
  • For the 5-year period, Madrigal Pharmaceuticals' Short-term Investments averaged around $384.9 million, with its median value being $263.0 million (2021).
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Short-term Investments plummeted by 8836.92% in 2022, and later surged by 186222.59% in 2023.
  • Madrigal Pharmaceuticals' Short-term Investments (Quarter) stood at $234.1 million in 2021, then tumbled by 88.37% to $27.2 million in 2022, then skyrocketed by 1862.23% to $534.2 million in 2023, then skyrocketed by 54.66% to $826.2 million in 2024, then decreased by 1.47% to $814.1 million in 2025.
  • Its last three reported values are $814.1 million in Q3 2025, $610.8 million for Q2 2025, and $659.4 million during Q1 2025.